Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 13/20 | 1.00 |
| ▸ | CA12 | O43570 | 4/20 | 0.66 |
| ▸ | CA1 | P00915 | 4/20 | 0.66 |
| ▸ | CA2 | P00918 | 4/20 | 0.66 |
| ▸ | CA9 | Q16790 | 4/20 | 0.66 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29747897 | 1.00 | VCAM1 (1.00) | VCAM1CA12CA1CA2CA9 | |
| Butane SCHEMBL9586852 | 0.92 | VCAM1 (0.84) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL28106126 | 0.88 | VCAM1 (0.77) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL8101212 | 0.85 | VCAM1 (0.74) | VCAM1CA12CA1CA2CA9 | |
| SCHEMBL10452716 | 0.85 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL29780388 | 0.85 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL809482 | 0.85 | VCAM1 (0.73) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL9323485 | 0.83 | VCAM1 (0.71) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL376610 | 0.83 | VCAM1 (0.71) | VCAM1NPBWR1MCHR1ALDH1A1 | |
| SCHEMBL30430066 | 0.83 | VCAM1 (0.71) | VCAM1NPBWR1MCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108037196-B | Detection method of 3-nitro-4- [ [ (tetrahydro-2H-pyran-4-yl) methyl ] amino ] benzenesulfonamide | 中山奕安泰医药科技有限公司 | 2020-06-23 | — | — | CN | claimed |
| CN-109776414-A | A kind of Bcl-2 protein inhibitor and its preparation method and application | 山东大学 | 2019-05-21 | — | — | CN | claimed |
| CN-109456231-A | A kind of preparation method of 2- nitro-chlorobenzene -4- sulfonamide | 临海市奥特休闲用品股份有限公司 | 2019-03-12 | — | — | CN | claimed |
| CN-109020846-A | O- replaces tyrosine Bcl-2 protein inhibitor and preparation method and application | 山东大学 | 2018-12-18 | — | — | CN | claimed |
| CN-104592064-A | Synthetic method of 2-aminophenol-4-sulfonamide | QINGDAO DOUBLE PEACH SPECIALTY CHEMICALS GROUP CO LTD | 2015-05-06 | — | — | CN | claimed |
| CN-1022333-C | Method and composition for refinement of metal | REM CHEMICALS INC (US) | 1993-10-06 | — | — | CN | claimed |
| US-RE34272-E | Oxalic acid, a thiocyanate salt, and a nitrobenzenesulfonate salt | REM CHEMICALS, INC. (US) | 1993-06-08 | — | — | US | claimed |
| EP-0395815-B1 | METHOD AND COMPOSITION FOR REFINEMENT OF METAL SURFACES | REM CHEMICALS, INC. (US) | 1993-06-02 | — | — | EP | claimed |
| EP-0395815-A1 | Method and composition for refinement of metal surfaces | REM CHEMICALS, INC. (US) | 1990-11-07 | — | — | EP | claimed |
| US-4906327-A | Method and composition for refinement of metal surfaces | REM CHEMICALS, INC. (US) | 1990-03-06 | — | — | US | claimed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12583853-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| EP-0013144-A1 | Substituted diphenylamine derivatives, compositions and herbicidal uses thereof, and processes for their preparation | ICI AUSTRALIA LIMITED (AU) | 1980-07-09 | — | — | EP | disclosed |
| US-4125368-A | Metallized monoazo dyes | TOMS RIVER CHEMICAL CORP. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4058515-A | Metallized phenyl-azo-naphthol compounds | TOMS RIVER CHEMICAL CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-3994873-A | Azo dyestuffs containing sulfonylamino-sulfonyl groups | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
| US-3935005-A | Composition and method for stripping gold and silver | AMERICAN CHEMICAL & REFINING COMPANY, INCORPORATED (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | VCAM1 2277/4885CA12 3306/4885CA1 1673/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | VCAM1 3182/4885CA12 1371/4885CA1 436/4885 |
| US-12583853-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | BCL3, BCL9, BCL6 | VCAM1 2376/4885CA12 2429/4885CA1 1353/4885 |
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | BCL3, BCL2A1, BCL6 | VCAM1 1933/4885CA12 3250/4885CA1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.